RadNet, Inc. (RDNT) AI Stock Analysis

RadNet, Inc. provides outpatient diagnostic imaging services across the United States. Established in 1981, the company offers medical imaging modalities including MRI, CT, PET, nuclear medicine, mammography, ultrasound, diagnostic radiology, and fluoroscopy. RadNet also develops and sells computerized systems for the diagnostic imaging industry, such as picture archiving communications systems (PACS). In addition, it integrates artificial intelligence into radiology practices, deploying AI suites for mammography interpretation and developing solutions for lung and prostate cancers. As of December 31, 2021, RadNet owned and managed 347 outpatient imaging centers across states including Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York.

RadNet expanded annual revenue from $1.32B in FY2021 to $2.04B in FY2025, reflecting a 5-year revenue CAGR of 13.7%. Operating margin declined from 6.3% in FY2021 to 4.5% in FY2025, while gross margin fell to 4.5% from 14.6% in FY2021. Net income moved from $24.7M in FY2021 to -$18.7M in FY2025, with EPS of $0.39. Over the trailing twelve months, revenue totaled $2.27B with an operating margin of 7.9% and EPS of -$0.27. In the latest quarter ended June 30, 2026, quarterly revenue grew 25.0% year-over-year, while quarterly earnings fell 49.1%.

As of June 30, 2026, RadNet held $726.3M in cash and short-term investments, with total debt of $2.18B and net debt of $1.46B. Shareholders' equity was $1.10B, yielding a debt-to-equity ratio of 1.99 and a current ratio of 1.48. In FY2025, the company generated $298.8M in operating cash flow and $85.6M in free cash flow after funding capital expenditures of $213.3M. In addition, its share count expanded 45.9% over a 5-year period.

RadNet trades at a forward P/E of 36.6x and an EV/EBITDA of 21.6x, compared to the median of its US-listed Healthcare peers of 17.3x and 12.0x, respectively. The stock's price-to-sales multiple stands at 2.4x, below the peer median of 4.1x. Over the past year, RadNet shares dropped 11.1%, trailing the S&P 500 return of 16.8%. Over a 5-year horizon, RDNT returned 139.1% against 83.0% for the S&P 500.

Wall Street coverage includes 6 Strong Buy ratings and 2 Buy ratings, with no Hold or Sell recommendations. The consensus mean price target is $94.62, representing a 37.5% premium to the last close of $68.80 on October 16, 2026. For the fiscal year ending December 31, 2026, analysts estimate revenue of $2.51B and EPS of $0.51, representing 31.9% earnings growth. Over the last four quarters, the company met or exceeded EPS estimates 2 times. The next earnings date is November 9, 2026.

This page is an AI-written research summary of RadNet, Inc. (RDNT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: RDNT income statement, RDNT balance sheet, RDNT key metrics, RDNT analyst forecast, RDNT chart. See the RDNT stock overview for the latest quote and news.